Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more) Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more) Digital Health Meets AI -CSE: ALEN.U (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nabriva Therapeutics PLC (EM) NBRVF

Healthcare Biotechnology
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:NBRVF)

Arbutus Appoints Two New Executives

GlobeNewswire July 10, 2023

Nabriva Therapeutics Provides Corporate Update

GlobeNewswire January 6, 2023

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

GlobeNewswire November 28, 2022

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2022

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

GlobeNewswire November 7, 2022

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

GlobeNewswire September 15, 2022

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

GlobeNewswire August 11, 2022

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire August 3, 2022
View More News ››

Opinion & Analysis (EXPM:NBRVF)

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

Streetwise Reports August 28, 2019

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

Streetwise Reports May 16, 2019

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

Streetwise Reports March 21, 2019

Target priced raised on 'undervalued' antibiotics developer

Streetwise Reports November 7, 2017
View More Opinion ››

Bullboard Posts (EXPM:NBRVF)

NBRV ..... Keep your eyes on the prize ; )

The "Siver Cup" is within reach  JMHO
Iseneschal - October 12, 2022

NBRV ...... Slowly slowly creeps the monkey ; )

Todays high is $2.80....... Remember ....keep your sights on that "Gap Fill" over $3.31  Still low volume on this Nano...
Iseneschal - October 6, 2022

NBRV ..... Keep that "Gap Target " in focus ; )

Starts at $3.28 Low volume runner ? Why not !!!!
Iseneschal - October 5, 2022

NBRV...... Now Mr. Maggot is making everyone squirm ; )

Volume is low however .....you could fit a Mack truck between the bid & ask ! So Mr. M is saying if you want to play this deal...
Iseneschal - October 5, 2022

NBRV .....Adding to position ; )

Cheers !
Iseneschal - October 5, 2022

NBRV ... Still in this Nano Float ; )

Not a seller Make note: The volume has increased (albeit low) ....it started about 1/2 hour ago....just an observation Stick and stay...
Iseneschal - October 4, 2022
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts